Epidemiology Articles

Gain free access to the latest articles on the NASH and NAFLD epidemic by a global expert community. ⌨

Cardiovascular disease in MAFLD versus NAFLD: a review

Authors: Kang MK, Lee YR, Jang SY et al
Published in Hepatol Int (April 2023)
Changing the terminology from NAFLD, non-alcoholic fatty liver disease, to MAFLD, metabolic dysfunction-associated fatty liver disease, has been an ongoing debate. MAFLD is based upon an individual having hepatic steatosis, as well as either type 2 diabetes mellitus, obesity (or being overweight) or if at a normal weight, two or more metabolic risk abnormalities.
Read More

The “Perfect” NASH Biomarker: an Unrealistic Pursuit?

Authors: Sebastiani G
Published in Lancet Gastroenterol Hepatol 2023
Seeking the perfect NASH biomarker may be unrealistic; versatility is key. A diverse biomarker pool adapts to varied clinical contexts and settings. FIB-4, a cost-effective marker, can be supplemented by complex multimarkers for NASH therapeutic trials. Embracing diagnostic imperfections is crucial for flexible biomarker algorithms.
Read More

Cardiovascular Risk in Patients with NAFLD and Inflammatory Bowel Diseases

Authors: Kablawi D, Aljohani F, Palumbo CS et al.
Published in Crohns Colitis 360 2023
NAFLD's prevalence in IBD patients raises concerns for cardiovascular risk. The study found doubled atherosclerotic cardiovascular disease risk in IBD patients with NAFLD. Transient elastography may predict cardiovascular risk in IBD patients. Targeted risk assessments are crucial for IBD patients with NAFLD.
Read More

T2D-Related Complications and its Impact on Fibrosis Levels: an Emerging Association?

Authors: Trivedi HD, Tran Q, Fricker Z et al.
Published in Annals of hepatology 2023
Patients with T2D complications have a 4.5x greater risk of developing fibrosis, independent of HbA1c levels. FIB-4 index can help identify diabetic patients at highest risk, improving primary care screening.
Read More

Asia, Middle East, North Africa: burden of NAFLD

Authors: Golabi P, Paik JM, AlQahtani S, et al.
Published in J Hepatol 2021
Using Global Burden of Disease data, P. Golabi et al. (Inova Health System, USA) aimed to assess the incidence, mortality, and disability-adjusted life years attributable to NAFLD-related liver complications in Asia, the Middle East and North Africa. As stated by the authors in their conclusion, “NAFLD is poised to contribute to a substantial...
Read More

NASH Epidemic: a call to action

Authors: Kanwal F, Shubrook JH, Younossi Z, et al.
Published in Gastroenterology 2021
NAFLD and NASH are common conditions with a rising burden. As pointed out by F. Kanwal et al. (Baylor College of Medicine, and Michael E. DeBakey Veterans Affairs Medical Center, Houston,USA), “yet there are significant management gaps between clinical guidelines and practice in patients with NAFLD and NASH. Further, there is no single...
Read More

NAFLD unawareness in US adults

Authors: Alqahtani SA, Paik JM, Biswas R, et al.
Published in Mol Metab 2021
MAFLD is closely related to disturbances in systemic energy metabolism, including insulin resistance and atherogenic dyslipidaemia. This review by J. Heeren and L Scheja (University Medical Center Hamburg-Eppendorf, Germany) discusses recent research addressing lipoprotein metabolism in the context of MAFLD...
Read More

Genetic and epigenetic factors determining NAFLD risk

Authors: Jonas W, Schurmann A.
Published in Mol Metab 2021
Predicting the individual risk of NAFLD and determining the probability of disease progression is the basis for further developing prevention and treatment strategies. This requires knowledge of the genetic and epigenetic modifiers of NAFLD for genotype-guided risk stratification...
Read More

Children with suspected NAFLD: negative for other causes of liver disease

Authors: Yodoshi T, Orkin S, Arce-Clachar AC, et al.
Published in Pediatrics 2021
T. Yodoshi et al. (Cincinnati Children's Hospital Medical Center, USA) aimed to determine the prevalence of alternative causes of liver disease in a multicenter, retrospective cohort of 900 children with overweight and obesity patients aged ≤18 years with overweight and obesity, referred for suspected NAFLD...
Read More

Treatment of 3 major risk factors and fibrosis stage regression

Authors: Yao VJH, Sun M, Rahman AA, et al.
Published in Clin Exp Hepatol 2021
Currently, no established hierarchy exists for the influence of metabolic risk factors on NAFLD progression. In this retrospective cohort study, V. J. H Yao et al. (CUNY School of Medicine/Sophie Davis Biomedical Education Program, New York, USA) investigated and ranked the independent and combined effects of three major risk...
Read More